AACC
Better health through laboratory medicine

SOUTHERN CALIFORNIA SECTION

SECTION MEETING – TUESDAY, MAY 20, 2014

SPORTS DRUG TESTING LABORATORIES: CATCHING THE DOPERS

DR. ANTHONY BUTCH, PH.D., DABCC, FACB, MT(ASCP)
PROFESSOR OF PATHOLOGY & LABORATORY MEDICINE, DAVID GEFFEN SCHOOL OF MEDICINE
DIRECTOR OF UCLA OLYMPIC ANALYTICAL LABORATORY

PHARMACOGENETIC TESTING IN CLINICAL PRACTICE: CURRENT STATE OF THE ART, EVIDENCE FOR UTILITY AND FUTURE DIRECTIONS

DR. NAISSAN HUSSAINZADA, PH.D
DIRECTOR OF PHARMACOGENETIC TESTING CLINICAL STRATEGY, MILLENNIUM LABORATORIES
ADJUNCT ASSISTANT PROFESSOR, SCHOOL OF PHARMACY, UNIVERSITY OF MARYLAND, BALTIMORE

Location:	**Agenda**:		**RSVP Required**
Phenomenex 411 Madrid Ave Torrance CA, 90501 Phone: 310-212-0555	4:00 – 5:00 PM 4:00 – 5:00 PM 5:00 – 6:00 PM 6:00 – 7:00 PM 7:00 – 9:00 PM	Board Meeting Phenomenex Tour Mixer & Posters Dinner Speakers	by Friday, May 16th, 2014 to socalaacc@gmail.com **Free Admission** (Sponsored by Phenomenex & AB SCIEX) Free Parking

Submitted for Two Hours Continuing Education (CE) credits

Unable to attend in person? Watch the presentations LIVE through WebEx!
Email socalAACC@gmail.com for more information

Learning Objectives: After the presentation, *Sports Drug Testing Laboratories: Catching the Dopers*, participants will be able to

1. Describe the elements of the World Anti-Doping Agency program and the prohibited list
2. Discuss the technologies used to detect doping
3. Explain the problems associated with the use of supplements
4. Identify the difficulties associated with staying ahead of athletes that dope

Learning Objectives: After the presentation, *Pharmacogenetic Testing in Clinical Practice: Current State of the Art, Evidence for Utility and Future Directions*, participants will be able to

1. Discuss the current status of pharmacogenetic biomarkers in medication management
2. Review current and emerging technologies for genotyping patients in the clinical setting
3. Review the clinical evidence for pharmacogenetic biomarkers in key diseases
4. Provide patient case examples of clinical implementation of specific gene-drug pairs